Neurofibroma, Plexiform: Clinical Trials

4 trials for Neurofibroma, Plexiform, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting, 1 completed, 1 recruiting. 4 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 34Active not recruiting 2, Completed 1, Recruiting 1

Follow Neurofibroma, Plexiform: new trials by email Literature Review of Neurofibroma, Plexiform trials Research Report on Neurofibroma, Plexiform

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas
TQ-B3234 capsules, TQ-B3234 placebo - Plexiform Neurofibroma
Phase 3RecruitingChia Tai Tianqing Pharmaceutical Group Co., Ltd.1772026-03-312026-05-27
FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas
Test group (Group A): FCN-159 8 mg, orally, once daily;, Control group (Group B): Placebo, orally, once daily; - Neurofibromatosis 1, Plexiform Neurofibroma
Phase 3Active not recruitingShanghai Fosun Pharmaceutical Industrial Development Co. Ltd.1672023-06-202025-03-06
Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas
Selumetinib, Placebo - Neurofibromatosis 1, Plexiform Neurofibroma (PN)
Phase 3Active not recruitingAstraZeneca1452021-11-192026-11-12
Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain
Acceptance and Commitment Therapy (ACT) - Neurofibromatosis Type 1, Plexiform Neurofibromas
Phase 3CompletedNational Cancer Institute (NCI)662015-07-072022-06-14

Narrower conditions

Neurofibromatosis 1 (3)

Broader conditions

Neoplasms (4)  ·  Neoplasms by Histologic Type (4)  ·  Neoplasms, Nerve Tissue (4)  ·  Nerve Sheath Neoplasms (4)  ·  Nervous System Diseases (4)  ·  Nervous System Neoplasms (4)  ·  Neurofibroma (4)  ·  Neuromuscular Diseases (4)  ·  Peripheral Nervous System Diseases (4)  ·  Peripheral Nervous System Neoplasms (4)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3)  ·  Genetic Diseases, Inborn (3)  ·  Heredodegenerative Disorders, Nervous System (3)  ·  Neoplastic Syndromes, Hereditary (3)  ·  Neurocutaneous Syndromes (3)

Interventions

AZD 6244 (1)  ·  Acceptance and Commitment Therapy (1)  ·  Control Groups (1)

Sponsors

AstraZeneca (1)  ·  Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1)  ·  National Cancer Institute (NCI) (1)  ·  Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (1)

Countries

China (3)  ·  United States (2)  ·  Australia (1)  ·  Brazil (1)  ·  Canada (1)  ·  France (1)  ·  Germany (1)  ·  Italy (1)  ·  Japan (1)  ·  Poland (1)  ·  Russia (1)  ·  Spain (1)  ·  United Kingdom (1)

Top investigators

Alice P. Chen, MD (1)  ·  Staci M Peron, Ph.D. (1)  ·  Wenbin Li, MD (1)

Results publications

PMID 40473450